This clinical trial is focused on studying the effects of the medication Clopidogrel on reducing the risk of developing Systemic Sclerosis in individuals who have specific immune system characteristics and experience Raynaud’s Phenomenon. Raynaud’s Phenomenon is a condition where some areas of the body, like fingers and toes, feel numb and cold in response to cold temperatures or stress. Systemic Sclerosis is a rare disease that involves the hardening and tightening of the skin and connective tissues. The study will compare the effects of Clopidogrel with a placebo to see if it can prevent the onset of Systemic Sclerosis over a period of five years.

Participants in the study will be randomly assigned to receive either Clopidogrel or a placebo. The medication will be taken orally in the form of film-coated tablets. The study will last for up to 24 months, during which participants will be monitored for any signs of Systemic Sclerosis and other related symptoms. The goal is to determine if Clopidogrel can effectively reduce the risk of developing this condition in people who are at higher risk due to their immune system profile and symptoms of Raynaud’s Phenomenon.

Throughout the study, participants will undergo regular check-ups to assess their health and any changes in their condition. The study aims to provide valuable information on whether Clopidogrel can be used as a preventive treatment for Systemic Sclerosis, potentially offering a new approach to managing this challenging disease. Participants’ health and safety will be closely monitored by medical professionals throughout the trial.